Coiled Therapeutics Forms Medical Advisory Board for Phase III Trial
51d ago|4 min readStandard
Fazen Markets Editorial Desk
Collective editorial team · methodology
biotechphase-iii-trial
Fazen Markets Editorial Desk
Collective editorial team · methodology
Trades XAUUSD on autopilot. Verified Myfxbook performance. Free forever.
Risk warning: CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. The majority of retail investor accounts lose money when trading CFDs. AiX is informational software — not investment advice. Past performance does not guarantee future results.
Coiled Therapeutics announced the formation of a high-profile medical advisory board on June 17, 2026. The board is tasked with guiding the clinical development strategy for CTX-101, the company's lead candidate for chronic neuropathic pain. This initiative precedes a planned Phase III clinical trial expected to commence in the fourth quarter of 2026, targeting a market exceeding 20 million patients in the United States alone.
Biotechnology firms typically assemble specialized medical advisory boards during the transition from mid-stage to late-stage clinical development. This strategic move often indicates a company is preparing for the complexities of a Phase III trial, which requires extensive patient recruitment and rigorous regulatory oversight. The last significant advisory board formation in the neuropathic pain sector occurred in October 2025 when Vertex Pharmaceuticals expanded its panel for a non-opioid analgesic.
The current macroeconomic backdrop features sustained volatility in biotech valuations, with the SPDR S&P Biotech ETF (XBI) trading 15% below its 52-week high. Despite this, investor interest remains focused on late-stage assets with clear regulatory pathways. Coiled's decision to establish the board now is a direct catalyst to de-risk the upcoming Phase III study by incorporating expert feedback on trial design and patient selection criteria.
This action is a proactive step to address investor concerns about clinical trial execution. By engaging key opinion leaders early, Coiled aims to enhance the trial's probability of success and build credibility ahead of potentially seeking partnership deals or additional financing.
Coiled Therapeutics secured a $150 million Series C financing round in Q1 2026 to fund its clinical programs. The neuropathic pain market is projected to reach $9.8 billion globally by 2028, growing at a compound annual growth rate of 6.2%. CTX-101 demonstrated a 35% reduction in pain scores versus placebo in its Phase II study involving 300 patients.
| Metric | Phase II Results | Phase III Target |
|---|---|---|
| Patient Cohort Size | 300 | 1,200+ |
| Primary Endpoint Success | Statistically Significant (p<0.01) | Meets FDA Safety & Efficacy Standards |
| Trial Duration | 12 weeks | 52 weeks |
The company's private valuation was last estimated at $1.2 billion. This compares to publicly-traded peers like Collegium Pharmaceutical (COLL), which holds a market capitalization of $950 million. The advisory board comprises six members, each with an average of over 20 years of experience in neurology and pain management.
Coiled's advisory board formation is a positive signal for the broader specialty pharmaceutical sector, particularly companies focused on non-opioid pain management. This development could increase scrutiny on publicly traded peers like Collegium Pharmaceutical (COLL) and Cara Therapeutics (CARA), potentially creating a more favorable valuation environment for late-stage private assets. The biotech sector often sees sentiment shifts based on regulatory and clinical milestones from emerging players.
A successful Phase III outcome for CTX-101 could negatively impact generic opioid manufacturers by accelerating the shift towards targeted therapies. The counter-argument is that Coiled remains a private company, limiting direct investment opportunities and making its progress a sentiment indicator rather than a direct trade. The primary risk involves the high failure rate of Phase III trials, estimated at nearly 30% across the industry.
Institutional flow data suggests venture capital firms are increasing their allocations to late-stage private biotech companies with defined paths to commercialization. This activity indicates a search for assets that are de-risked relative to early-stage startups but offer higher potential returns than large-cap pharmaceutical stocks.
The next critical catalyst for Coiled Therapeutics is the official initiation of its Phase III trial, expected by November 2026. Investors should monitor the FDA's website for the public posting of the trial's clinicaltrials.gov identifier, which will provide detailed protocol information. Key levels to watch include patient enrollment rates once the trial begins, as slow recruitment is a common hurdle.
The Q3 2026 earnings season for public pain management companies like Pfizer (PFE) and Eli Lilly (LLY) may offer commentary on the competitive landscape. Any announcements regarding partnership discussions or further financing rounds for Coiled will serve as secondary catalysts. The outcome of the FDA's advisory committee meeting for a competing neuropathic pain drug, scheduled for August 2026, will also provide a relevant benchmark for regulatory sentiment.
A medical advisory board provides independent expert guidance on clinical trial design, patient recruitment strategies, and data interpretation. Members are typically key opinion leaders in their medical fields who help ensure a trial is scientifically sound and has a higher likelihood of regulatory approval. Their involvement adds credibility and can help a company manage complex regulatory requirements.
Phase II trials primarily assess a drug's efficacy and optimal dosing in a few hundred patients. Phase III trials are significantly larger, involving thousands of patients, and are designed to confirm efficacy, monitor side effects, and compare the drug to commonly used treatments. Success in Phase III is the final step before a company can submit a New Drug Application to the FDA for market approval.
Investing in private biotech carries high risk due to the binary nature of clinical trial outcomes. A failed Phase III trial can render a company's lead asset worthless. Liquidity is also a major concern, as investments are typically locked up for years until an initial public offering or acquisition occurs. Retail investors generally gain exposure through biotech-focused exchange-traded funds or mutual funds that may hold positions in venture capital funds.
Coiled Therapeutics is executing a standard biotech playbook to de-risk its pivotal Phase III trial.
Disclaimer: This article is for informational purposes only and does not constitute investment advice. CFD trading carries high risk of capital loss.
AiX is our free MetaTrader 4 Expert Advisor. Verified Myfxbook performance. No subscription. No fees. XAUUSD breakout engine.
Position yourself for the macro moves discussed above
Start TradingSponsored
Open a demo account in 30 seconds. No deposit required.
CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.